Clinical Trial Spotlight: ALTO-300

The ALTO-300-201 study is a Phase 2 clinical trial evaluating the safety and efficacy of ALTO-300 (agomelatine), an investigational adjunctive treatment for Major Depressive Disorder (MDD). This trial is part of a broader initiative to integrate precision psychiatry into clinical practice by leveraging biomarkers to optimize treatment outcomes.

Key Study Features:

• Design: 6-week double-blind, placebo-controlled phase followed by an optional 8-week open-label extension with guaranteed ALTO-300 administration.
• Population: Adults aged 18–70 with moderate to severe MDD, currently on a single antidepressant (SSRI, SNRI, or bupropion) for at least 6 weeks.
• Biomarker Integration: The study incorporates EEG, DNA samples, and cognitive assessments to explore predictive markers of treatment response.

Click here to read more.